Becton, Dickinson & Co. Hits New 52-Week Low at $162.50

Becton, Dickinson & Co., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 162.50 as of November 6, 2025. This decline marks a significant downturn for the stock, which has experienced a 25.94% decrease over the past year, contrasting sharply with the S&P 500's performance of 17.53% during the same period.
The company's market capitalization stands at USD 70,270 million, categorizing it as a large-cap entity. Becton, Dickinson & Co. has a price-to-earnings (P/E) ratio of 33.00, indicating a premium valuation relative to its earnings. The stock also offers a dividend yield of 2.53%, reflecting its commitment to returning value to shareholders.

Despite a relatively low debt-to-equity ratio of 0.73, the company has faced challenges in achieving long-term growth, with operating profit increasing at an annual rate of just 5.16% over the last five years. Additionally, the stock has shown consistent underperformance against the S&P 500 benchmark over the past three years, further highlighting the current market dynamics affecting Becton, Dickinson & Co.